[email protected]

+44 (0)20 3773 4895

logologologo
  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • PGCert in Obesity Care
    • PGCert in Digital Health
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Monthly News Bulletins
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login

No products in the cart.

logologologo
  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • PGCert in Obesity Care
    • PGCert in Digital Health
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Monthly News Bulletins
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login

No products in the cart.

  • About Us
    • The College
    • Advisory Board
    • Our Faculty and Team
    • Intelligence Hub
  • Topic Areas
    • Obesity Care
    • Digital Health
    • Behaviour Change
  • Courses
    • CPD Short Courses
    • PGCert in Obesity Care
    • PGCert in Digital Health
  • Apply
    • Postgraduate Qualification in Obesity Care
    • Postgraduate Qualification in Digital Health
    • FAQs
  • Resources
    • News
    • Our Publications
    • Monthly News Bulletins
    • Funding Options
  • Contact Us
    • Contact Us
  • Student Login
May 11, 2016 by Nigel Hinchliffe GLP-1RAs & Medications 0 comments

Does nanoparticle drug delivery offer hope to obese patients?

Researchers at MIT and Brigham and Women’s Hospital have developed nanoparticles to deliver anti-obesity drugs. In a study using a mouse model, researchers were able to effectively deliver drugs which converted white adipose tissue into brown adipose tissue – thereby helping to burn off the fat. The drugs also increased vasculature to these areas, allowing for more drugs to be subsequently delivered to the correct areas, helping to avoid unwanted side effects in other parts of the body.

The researchers are particularly encouraged to know that they can deliver the drug to particular areas and have an overall positive effect. After treating the mice intravenously, it was noted that those on a high-fat diet lost approximately 10% of their body weight, with cholesterol and triglyceride levels also dropping. Furthermore, the treatment did not cause any side effects to the mice. Further research involves looking into an easier delivery approach of the nanoparticles, such as delivering them by mouth – something that has proven difficult in the past. Overall, the authors are reassured by their results and are looking forward to taking the research further.

PREV
NEXT

Related Posts

Girl taking a pill.
November 13, 2023
AstraZeneca makes big push into obesity treatment with new pill partnership
Read More
Basel, Switzerland.
December 6, 2023
Swiss pharmaceutical giant Roche enters obesity drug race with $2.7 billion Carmot deal
Read More
GLP-1 pens on a white table.
March 11, 2026
Switching GLP-1 Medications May Improve Long-Term Engagement in Obesity Treatment, Real-World Study Suggests
Read More
Woman experiencing menopause.
February 3, 2026
Combination of Hormone Therapy and Tirzepatide Linked to Greater Weight Loss After Menopause, Study Finds
Read More

CCH LINKS

FAQ
HOW TO APPLY
ACADEMIC ADVISORY BOARD
FACULTY AND STAFF
TERMS & CONDITIONS
CCH EDUCATION SERVICES

OUR PARTNERS

NOF
Haringey Obesity Alliance
Skills Active
CPD UK
ASO
REPS
Southwark
DIT
Healthcare Uk
OAC

ABOUT CCH

CONTACT US
[email protected]
+44 (0)20 3773 4895
Technopark, 90 London Road, LONDON, SE1 6LN
 

© The College of Contemporary Health